欢迎来到天天文库
浏览记录
ID:53736342
大小:285.92 KB
页数:4页
时间:2020-04-21
《子宫颈癌放疗同步化疗治疗中顺铂用药临床观察.pdf》由会员上传分享,免费在线阅读,更多相关内容在应用文档-天天文库。
1、中闽医科大学学报第42卷第l2期2013年12月JournalofChinaMedicalUniversityVo1.42No.12Dec.2013·1087··论著·子宫颈癌放疗同步化疗治疗中顺铂用药临床观察张文陆,王言,崔慧霞(辽宁医学院1.附属第一医院综合八病区,2.护理学院,辽宁锦州121001)摘要目的观察放疗与顺铂同步化疗治疗子宫颈鳞癌中,顺铂用药周期数、用药剂量、近期疗效和不良反应。方法回顾分析51例Ibl~IIIb期子宫颈鳞癌患者,行盆腔野放疗(剂量45~50Gy/5周),同时应用顺铂每周方案(顺铂30mg/m,每周1次,静脉滴注)进行化疗,35例Ibl~
2、lIb子宫颈鳞癌单纯放疗,观察其近期疗效和不良反应,记录放化同步治疗组患者应用顺铂的周期数及顺铂剂量。结果应用DDP30mg/m每周1次放疗化疗同步治疗的中位化疗周期为4周,与单纯放疗组相比,放化同步治疗患者的白细胞计数显著低于放疗组,恶心呕吐的发生率显著高于放疗组,差异具有统计学意义(P3、癌治疗有着较好的临床疗效。关键词子宫颈癌;顺铂;放化同步治疗中图分类号R737.3文献标志码A文章编号0258—4646(2013)12—1087—04网络出版地址http://www.enki.net/kcms/detail/21.1227.R.20131230.1053.008.htmlClinicalObservationofCisplatininCervicalCancerRadiotherapySynchronousChemotherapyZHANGWen.1u,WANGYan,CUIHui—xi~(1.TheFirstAfiliatedHospitalofLi4、aoningMeScalColege,Jinzhou121001,China;2.NursingSchoolofLiaoningMedicalCollege,Jinzhou121001,China)AbstractObjectiveToobservethenumberofcyclesofcisplafinmedication,medicationdose,efficacyandadversereactionsintheehemothera—PYofcervicalcancerradiotherapysynchronous.MethodsAretrospectiveanal5、ysiswasperformed,including51easesofIbltotheSbphaseeer—vicalcancerpatientswithpelvicfieldradiotherapy(doseof45to50Gy/5weeks),synchronouschemotherapy,weeklycisplatin(cisplatin30mg/m2weeklyintravenousinfusion)treatment,andanother35casesofIbltombcervicalcancerwithradiothempyonly.Theeficacyand6、adve~ere—actionswererecorded.ResultsDDPWasadministratedatadoseof30mg/m2onceaweekinthecervicalcancerradiotherapysynchronousehemo—therapy,themediancycleofchemotherapyisfourweeks,thepatientSleukocyteeoun~ofradiotherapysynchronouschemotherapygroupweresig—nificanflylowerthantheradiotherapygrou7、p,theincidenceofnauseaandvomitingwassignificantlyhigherintheradiotherapysynchronouschemo—therapygroup,thediferenceswerestatisticallysignificant(P<0.05).However,inthelong—termeficacy,radiotherapysynchronouschemotherapyshoweda3-yeardisease—freesurvivalrateof92.7%.5-ye
3、癌治疗有着较好的临床疗效。关键词子宫颈癌;顺铂;放化同步治疗中图分类号R737.3文献标志码A文章编号0258—4646(2013)12—1087—04网络出版地址http://www.enki.net/kcms/detail/21.1227.R.20131230.1053.008.htmlClinicalObservationofCisplatininCervicalCancerRadiotherapySynchronousChemotherapyZHANGWen.1u,WANGYan,CUIHui—xi~(1.TheFirstAfiliatedHospitalofLi
4、aoningMeScalColege,Jinzhou121001,China;2.NursingSchoolofLiaoningMedicalCollege,Jinzhou121001,China)AbstractObjectiveToobservethenumberofcyclesofcisplafinmedication,medicationdose,efficacyandadversereactionsintheehemothera—PYofcervicalcancerradiotherapysynchronous.MethodsAretrospectiveanal
5、ysiswasperformed,including51easesofIbltotheSbphaseeer—vicalcancerpatientswithpelvicfieldradiotherapy(doseof45to50Gy/5weeks),synchronouschemotherapy,weeklycisplatin(cisplatin30mg/m2weeklyintravenousinfusion)treatment,andanother35casesofIbltombcervicalcancerwithradiothempyonly.Theeficacyand
6、adve~ere—actionswererecorded.ResultsDDPWasadministratedatadoseof30mg/m2onceaweekinthecervicalcancerradiotherapysynchronousehemo—therapy,themediancycleofchemotherapyisfourweeks,thepatientSleukocyteeoun~ofradiotherapysynchronouschemotherapygroupweresig—nificanflylowerthantheradiotherapygrou
7、p,theincidenceofnauseaandvomitingwassignificantlyhigherintheradiotherapysynchronouschemo—therapygroup,thediferenceswerestatisticallysignificant(P<0.05).However,inthelong—termeficacy,radiotherapysynchronouschemotherapyshoweda3-yeardisease—freesurvivalrateof92.7%.5-ye
此文档下载收益归作者所有